Prometheus Unlikely To Sway Fed. Circ.'s Myriad Ruling
The Federal Circuit seems unlikely to change its previous finding that breast cancer genes isolated by Myriad Genetics Inc. are patentable, attorneys said after Friday's oral arguments on whether the U.S....To view the full article, register now.
Already a subscriber? Click here to view full article